CYTOPIA DOSES 1st PHASE Ib/II BRAIN CANCER PATIENT
November 20th 2008 08:22
Monday November 17, 2008
Daily news on ASX-listed biotechnology companies
* ASX, BIOTECHS DOWN: PHYLOGICA UP 56%, LABTECH DOWN 23%
* BIOTA LANI PHASE III TRIALS READY FOR ENROLMENT
* MEDICAL THERAPIES OFFERS SHARE PLAN AT 4¢ A SHARE
* CYTOPIA DOSES 1st PHASE Ib/II BRAIN CANCER PATIENT
* PROGEN SPIN-OUT PHARMASYNTH FOR SALE
* DR MERVYN JACOBSON INCREASES IN GENETIC TECHNOLOGIES
* FMR, FIDELITY REDUCES TO 9.7% IN CSL
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
CYTOPIA
Cytopia has begun dosing patients in its phase Ib/II study of CYT997, to treat glioblastoma multiforme, an aggressive brain cancer.
Cytopia says the glioblastoma multiforme clinical trial is the company’s first phase II efficacy study in highly vascular, solid tumor indications and the first time the company’s novel vascular-disrupting anticancer agent, CYT997 is being investigated in a tumor of the central nervous system.
Cytopia said glioblastoma multiforme was treated by surgical resection, and/or radiation and chemotherapy.
Despite these treatments, the condition recurs in most patients resulting in significantly limited life expectancy, the company said.
Cytopia said glioblastoma multiforme tumors were highly vascular, rendering them potentially susceptible to destruction by an anti-vascular agent such as CYT997.
The clinical study will investigate the activity of CYT997 in combination with two other marketed anticancer agents in about 30 patients.
The director of oncology at Melbourne’s Frankston Hospital, Dr Jason Lickliter, is the program’s study chairman.
Cytopia said it was “well advanced” to opening its second clinical site for the study at a cancer centre in Sydney with enrolment expected “within weeks”.
The company said it intended to file the requisite submissions to enable dosing at two additional sites in Australia to begin early in 2009, with US and European clinical sites also being assessed for the later stages of the study.
Cytopia said the trial followed the conclusion of the company’s phase I safety study for intravenous CYT997, in which a prolonged delay in tumor growth was observed in seven of the study’s 31 advanced cancer patients (see Biotech Daily; November 13, 2007).
Cytopia was untraded at 15 cents.
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 28 |
| Vote |
Shared on
Add To: 
Subscribe to this blog
